Results 191 to 200 of about 26,268,555 (308)

First-line Treatment for AOMT [PDF]

Ear, Nose & Throat Journal, 2005
openaire   +1 more source

Laser trabeculoplasty as first-line glaucoma treatment [PDF]

The Lancet, 2019
Jonathan W, Young, Joesph, Caprioli
openaire   +2 more sources

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Mechanisms of first-line treatment resistance in diffuse large B-cell lymphoma. [PDF]

Front Immunol
Zhan Z, Li P, Liu Y, Zhen C, Zhang Y, Bai O.   +5 more
europepmc   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Is endoscopic submucosal dissection a first-line treatment for anal squamous cell carcinoma? [PDF]

Endosc Int Open
Gkegkes ID, Iavazzo C, Stamatiadis AP.
europepmc   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

The multifaceted roles of lysosomes in cancer

Molecular Oncology, EarlyView.
Lysosomes support cancer cell adaptation by integrating macromolecule degradation and nutrient recycling with nutrient sensing, inter‐organelle communication and immune regulation. These interconnected functions can promote tumour growth, stress tolerance and therapy resistance, while also creating context‐dependent vulnerabilities that may be ...
Jia Li, Kevin M. Ryan
wiley   +1 more source

AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma. [PDF]

Blood Adv
Övergaard N, Lia K, Collin J, Asdahl PH, Wikman P, Glimelius I, Lagerlöf I, Johansson AS, Hansson L, Enblad G, Linderoth J, Goldkuhl C, Jerlström U, Fosså A, Kamper P, Molin D.   +15 more
europepmc   +1 more source

Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses. [PDF]

J Immunother Cancer
Ma JT, Sun L, Zhang LY, Huang LT, Zhang SL, Sun N, Dong YY, Li XH, Yue Y, Yang MQ, Jiang JY, Feng J, Han X, Wu YT, Wang SW, Jiang YT, Guan ST, Chen XM, Han CB.   +18 more
europepmc   +1 more source